1. Home
  2. MIRM vs NOVT Comparison

MIRM vs NOVT Comparison

Compare MIRM & NOVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$64.32

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Logo Novanta Inc.

NOVT

Novanta Inc.

HOLD

Current Price

$118.62

Market Cap

3.8B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
NOVT
Founded
2018
1968
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.8B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
NOVT
Price
$64.32
$118.62
Analyst Decision
Strong Buy
Hold
Analyst Count
11
1
Target Price
$87.55
$133.00
AVG Volume (30 Days)
616.7K
496.2K
Earning Date
11-04-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.46
Revenue
$471,794,000.00
$960,311,000.00
Revenue This Year
$53.78
$5.10
Revenue Next Year
$19.91
$6.75
P/E Ratio
N/A
$82.39
Revenue Growth
53.66
4.07
52 Week Low
$36.88
$98.27
52 Week High
$78.55
$173.16

Technical Indicators

Market Signals
Indicator
MIRM
NOVT
Relative Strength Index (RSI) 35.49 58.13
Support Level $63.66 $114.19
Resistance Level $66.77 $121.95
Average True Range (ATR) 2.99 3.36
MACD -0.69 1.16
Stochastic Oscillator 9.63 81.92

Price Performance

Historical Comparison
MIRM
NOVT

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About NOVT Novanta Inc.

Novanta Inc manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The firm operates in two segments: Automation Enabling Technologies and Medical Solutions. It generates the majority of its revenue from the Medical Solutions segment that designs, manufactures, and markets a range of medical-grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; and wireless technologies. The firm generates the majority of its revenue from the United States and Europe.

Share on Social Networks: